Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Novo Nordisk has provided an update on the developmental progress of a pair of new insulin therapies that are currently involved in phase III trials.
The pharmaceutical company, which specialises in diabetes treatments, has completed the final phase IIIa trial for a new combination therapy called IDegLira, thus concluding its phase IIIa study programme for the drug.
IDegLira is a fixed-ratio combination of insulin degludec - a once-daily new-generation basal insulin analogue with an ultra-long duration of action marketed under the name Tresiba - and the liraglutide-based Victoza, a once-daily human GLP-1 analogue.
http://www.zenopa.com/news/80151290...ss-phase-iii-development-of-insulin-therapies
The pharmaceutical company, which specialises in diabetes treatments, has completed the final phase IIIa trial for a new combination therapy called IDegLira, thus concluding its phase IIIa study programme for the drug.
IDegLira is a fixed-ratio combination of insulin degludec - a once-daily new-generation basal insulin analogue with an ultra-long duration of action marketed under the name Tresiba - and the liraglutide-based Victoza, a once-daily human GLP-1 analogue.
http://www.zenopa.com/news/80151290...ss-phase-iii-development-of-insulin-therapies